Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Subscribe To Our Newsletter & Stay Updated